Restoration of leukomonocyte counts is associated with viral

clearance in COVID-19 hospitalized patients

- 4 Xiaoping Chen¹, Jiaxin Ling², Pingzheng Mo¹, Yongxi Zhang¹, Qunqun
- 5 Jiang¹, Zhiyong Ma¹, Qian Cao¹, Wenjia Hu¹, Shi Zou¹, Liangjun Chen³,
- 6 Lei Yao⁴, Mingqi Luo¹, Tielong Chen¹, Liping Deng¹, Ke Liang¹, Shihui
- 7 Song¹, Rongrong Yang¹, Ruiying Zheng¹, Shicheng Gao¹, Xien Gui¹,
- 8 Hengning Ke¹, Wei Hou⁴, Åke Lundkvist², Yong Xiong¹
- 10 ¹ Department of Infectious Diseases, Zhongnan Hospital of Wuhan
- 11 University, No.169, Donghu Road, Wuchang District, 430071 Wuhan,
- 12 Hubei Province, China

1

2

3

- ² Department of Medical Biochemistry and Microbiology, Zoonosis
- 14 Science Center, University of Uppsala, Uppsala, Sweden
- ³ Department of Laboratory Medicine, Zhongnan Hospital of Wuhan
- 16 University, Wuhan, People's Republic of China
- ⁴ State Key Laboratory of Virology/ Institute of Medical Virology/ Hubei
- 18 Province Key Laboratory of Allergy and Immunology, School of Basic
- 19 Medical Sciences, Wuhan University, 185 Donghu Road, Wuhan 430071,
- 20 Hubei Province, China

21 22 23 Corresponding to: 24 Xiaoping Chen, MD & PhD E-mail address; alacken@126.com 25 26 Tel: 86-27-67812880 Address: Department of infectious diseases, Zhongnan Hospital of 27 Wuhan University, No.169, Donghu Road, Wuchang District, Wuhan 28 29 City, Hubei Province, P.R China. 30 31 Yong Xiong, MD & PhD E-mail address; yongxiong64@163.com 32 33 Tel: 86-27-67812880 Address: Department of infectious diseases, Zhongnan Hospital of 34 Wuhan University, No.169, Donghu Road, Wuchang District, Wuhan 35 City, Hubei Province, P.R China. 36 37 38

Summary

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

Background: Viral clearance is one important indicator for the recovery of SARS-CoV-2 infected patients. Previous studies have pointed out that suboptimal T and B cell responses can delay viral clearance in MERS-CoV and SARS-CoV infected patients. The role of leukomonocytes in viral clearance of COVID-19 patients is not yet well defined. Methods: From January 26 to February 28, 2020, an observational study was launched at the Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China. We enrolled 25 laboratory-confirmed COVID-19 patients, whose throat-swab specimens were tested positive for SARS-CoV-2 infection by qRT-PCR. To investigate the factors that contribute to the viral clearance, we comprehensively analyzed clinical records, counts of lymphocyte subsets including CD3+, CD4+, CD8+ T cells, B cells and NK cells in the patients who successfully cleared SARS-CoV-2, and compared to those that failed to, after a standardized treatment of 8-14 days. Findings: In 25 enrolled COVID-19 patients, lymphopenia was a common feature. After the treatment, 14 out of the 25 enrolled patients were tested negative for SARS-CoV-2. The patients that cleared the infection had restored the numbers of CD3+, CD4+, CD8+ T cells and B

- 59 cells as compared to the still viral RNA positive patients, while the
- 60 recovered patients had a higher count of leukomonocytes.
- 61 Conclusions: By comparison of leukomonocytes counts in COVID-19
- patients at different stages of the disease, we found that CD3+, CD4+,
- 63 CD8+ T cells and B cells appear to play important roles in viral clearance.
- The restoration of leukomonocytes counts from peripheral blood can be
- used as prognosis for the recovery of an COVID-19 infection. We
- propose that restoration of leukomonocytes counts can be added to the
- 67 COVID-19 diagnostic guidance as a criterion for releasing and
- 68 discharging patients.
- 69 **Keywords.** COVID-19; SARS-CoV-2, leukomonocytes; viral clearance.

70 Funding

- 71 This study was funded by the Zhongnan Hospital of Wuhan University
- 72 Science, Technology and Innovation Seed Fund, grant number
- 73 znpy2018007 and the Swedish Research Council, grant number 2017-
- 74 05807. The funders had no role in study design, data collection or
- analysis, decision to publish or preparation of the manuscript. The authors
- 76 declared no competing interests.

Introduction

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

In December 2019, a cluster of novel coronavirus-associated pneumonia cases was emerging in Wuhan, China [1]. The disease rapidly spread from Wuhan and caused a wide epidemic in China. The World Health Organization (WHO) has recently named the disease as Coronavirus Disease-2019 (COVID-19) [2]. The etiology of the disease is a novel β coronavirus, taxonomically named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Until February 29, 2020, SARS-CoV-2 causes an epidemic worldwide. More than 80,000 people in over 60 countries or territories have been contracted of COVID-19, and more than 3000 people have died [3]. The clinical manifestations of COVID-19 cases range from an asymptomatic course to serve acute respiratory symptoms and even acute respiratory failure [4-7]. Transmission occurs from human to human with nosocomial transmissions. The incubation time of COVID-19 has been reported from 0 to 24 days and also asymptomatic carriers can be infectious [8]. As a zoonotic virus, the natural host of SARS-CoV-2 is believed to be bats [9], however, the process of cross-species transmission(s) is still not known. The very first cases were associated with the Huanan Seafood Wholesale Market in Wuhan, China [10]. There is no effective antiviral

drug available yet. Although the pathogenesis of COVID-19 is still unclear, lymphopenia has been found in most COVID-19 patients [10-12]. This feature has also been found in the other two fatal human coronavirus infections caused by severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) [13, 14]. Previous studies showed that T cells, especially CD4+ and CD8+ T cells, play a significant antiviral role in balancing the combat against MERS-CoV or SARS-CoV infections [15]. These results suggested that leukomonocytes counts could be critical indicators associated with severity and the disease outcome. In this study, we retrospectively analyzed 25 COVID-19 cases to elucidate the dynamic of lymphocyte subset changes in the peripheral blood and their roles during the viral clearance.

Methods

Study design

From January 26 to February 28, 2020, 25 COVID-19 patients who had

been repeatedly analyzed for lymphocyte subsets and SARS-CoV-2 RNA

were enrolled in the study. Informed consents were obtained from all

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

patients upon admission to the Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China. Data collection The medical records, including epidemiological and demographic information, clinical manifestations, laboratory data, and outcome of disease, were collected. To avoid subjective biases, two investigators reviewed the data independently and made a final consensus. Peripheral blood (100 µl) was collected from patients at admission to hospital and after 7 - 10 days of standard therapy (Version 6, 2020 Feb 18, http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351 d7da8aefc2.shtml). Lymphocyte subsets such as CD3+, CD4+, CD8+ T cells, B cells and NK cells were stained by using the BD MultitestTM IMK kit (BD Ltd., San Jose, CA, USA) according to the manufacturer's instruction. The lymphocyte subset analyses were performed by flow cytometry (BD FACSCantoTM II Flow Cytometer). Serial throat-swab samples were taken from patients at the admission to hospital during 8 - 14 days of standardized treatment (see Table 1) according to the recommendation in the guideline. The swab samples

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

were placed in 150 µL of virus preservation solution and viral RNA subsequently extracted as described earlier [5, 16]. Two target genes of the SARS-CoV-2 genome, including the open reading frame 1ab (ORF1ab) and the nucleocapsid protein (N) gene, were simultaneously amplified and tested in the real-time RT-PCR assay by using a SARS-CoV-2 nucleic acid detection kit according to the manufacturer's protocol (Shanghai Bio-Germ Medical Technology Co Ltd, Shanghai, China). The reaction mixture consisted of 12 µL reaction buffer, 4 µL of enzyme solution, 3 µL of diethyl pyrocarbonate-treated water, 2 µL of RNA template, and 4 µL of probe/primers solution, which contained two sets of probe primers: one set targets towards to ORF1ab (forward prime 5'-CCCTGTGGGTTTTACACTTAA-3'; primer 5'reverse ACGATTGTGCATCAGCTGA-3'; and the probe 5'-VIC-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'), and another primer targets towards to N (forward 5'-GGGGAACTTCTCCTGCTAGAAT-3'; 5'primer reverse CAGACATTTTGCTCTCAAGCTG-3'; and the probe 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'). The results of the real-time RT-PCR analyzes were interpreted as: a cycle threshold value (Ct-value) less than 37 was defined as a positive result; a Ct-value of 40 or more was defined as a negative result; a

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

medium load result, defined as a Ct-value of 37 to less than 40, required another test for confirmation. The patients who repeatedly tested SARS-CoV-2 RNA negative for at least two times with an interval of more than 1 day were regarded as viral negative. These diagnostic criteria were based on the recommendation by the National Institute for Viral Disease Control Prevention, China and (http://ivdc.chinacdc.cn/gjhz/jldt/202002/P020200209712430623296.pdf). Statistical analysis We used the SPSS 17.0 software package for the statistical analyses. We used X² tests or Fisher's exact tests for categorical variables. For measurement of the data, a normal distribution was tested first and then proceeded to t-test, expressed as the mean ± standard deviations; otherwise the Mann-Whitney U test was used for non-normal distribution data, expressed in terms of median (25%–75% interquartile range, IQR). A p value of < 0.05 was considered statistically significant. The principle of medical ethics This study was approved by the ethics board in Zhongnan Hospital of Wuhan University, Wuhan, China (No.2020011).

Results

178

182

187

189

190

194

195

196

197

179 Baseline Characteristics of COVID-19 patients 180 A total of 25 patients, 11 men and 14 women were enrolled in this study 181 (Table 1). The ages of the patients spanned from 25 to 80 years (average 51.4±16.6 years). Fourteen people described a previous exposure history to the source of infection, either from the Huanan Seafood Wholesale 183 184 Market or through direct contacts with COVID-19 patients. The most 185 common symptoms at the onset of illness were: fatigue (80.0%), fever 186 (37.4–39.1°C, 75.0%), myalgia (68.0%), cough (64.0%), and less common: dyspnea (28.0%) and diarrhea (20.0%). Seven cases had underlying diseases such as hypertension, cardiovascular disease, 188 diabetes, malignancy or chronic liver disease (Table 1). Laboratory analysis before and after treatment 191 Laboratory analysis were performed before the treatment. biochemical included alanine 192 tests aminotransferase, aspartate 193 aminotransferase, aspartate aminotransferase, creatinine, and D-dimer, which all were found normal (Table 2). However, blood counts of the patients showed leucopenia $(4.5\pm1.9 \times 10^9/L)$ and lymphopenia (< 1.3)

 $\times 10^{9}$ /L). The counts of CD3+ T cells, CD4+ T cells, CD8+ T cells, B

cells, and NK cells were found lower than normal values. Interleukin-6

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

had increased to a mean of 16.1 (3.7 - 31.4) pg/ml. Five patients had an increase of procalcitonin ($\geq 0.05 \text{ ng/mL}$) (Table 2). The treatment was mainly of supportive care (Table 1). Twenty-four patients were given antiviral therapy including arbidol (orally, 200 mg, three times per day), and oxygen support. Antibiotic therapy, both orally and intravenous, were given as described in Table 1. Fourteen patients received corticosteroids to suppress an excessive inflammatory activation. After standardized treatment of 8–14 days, according to the laboratory analysis of viral RNA, fourteen patients showed viral clearance and 11 patients were still positive for SARS-CoV-2 viral RNA (Table 1). When comparing the group that showed viral clearance and the group that failed, we found no significant association to sex, epidemiological exposure history, comorbidities, onsets of signs and symptoms, or treatment, but with the age and days of hospitalization. The mean days of hospitalization in the group that showed viral clearance were 12 days (10.0 - 15.0), which was shorter as compared to the group that failed to clear the virus, for which the average days were 21 (18.0 - 23.0) days. Age can play an important role during the viral clearance: patients without viral clearance were older (60.2±16.9, y) than patients with viral

217 clearance (44.5±13.0 y), showing a statistically significant difference 218 (Table 1). 219 Association between peripheral lymphocyte counts and disease 220 outcomes 221 Since lymphopenia was found in all the patients in the current study and 222 also earlier reported elsewhere [10], we further analyzed the association 223 between peripheral lymphocyte counts and disease outcomes. In the 14 224 patients with viral clearance after the 8 - 14 days of treatment, the counts 225 of CD3+ T cells, CD4+ T cells, CD8+ T cells, and B cells were restored 226 close to normal levels and with a significant difference as compared to 227 the counts at admission in 12 patients. In the remaining 2 patients with 228 viral clearance the leukomonocytes counts were still at low levels (Figure 229 1, A-E). However, in the patients without viral clearance (No.=11), no 230 differences were seen before and after treatment regarding the CD3+, 231 CD4+, CD8+, B, and NK cell counts (Figure 1, F-J). The association 232 between peripheral lymphocyte counts and viral detection suggested that 233 higher counts of CD3+ T cells, CD4+ T cells, CD8+ T cells, and B cells 234 had a significant impact on the viral clearance.

To further monitor the disease outcome of those 11 patients who were still positive for SARS-CoV-2 virus RNA, we extended the same treatment to 15 – 23 days (Figure 2). At 15 –23 days, 7 patients were negative for viral RNA detection (data for leukomonocyte subsets was available for 6 of these 7 patients), but 4 patients were still positive (all these four had been tested for leukomonocyte subsets). The 4 viral RNA positive patients had low counts of CD3+ T cells ($< 1200 \times 10^9$ /L), CD4+ T cells ($< 700 \times 10^9$ /L), CD8+ T cells ($< 500 \times 10^9$ /L), B cells (< 400 $\times 10^9$ /L), and NK cells (< 400 $\times 10^9$ /L). Due to the small sample size, no statistically significant differences for the cell counts were observed, except for the NK cell counts, which showed a significant decrease in the 4 viral RNA positive patients (Figure 2, J). However, we found a similar trend that the increased counts of CD3+ T cells and CD8+ T cells corresponded to cases which were negative for viral RNA detection (5 out of 6). One case that still had low counts of CD3+ T cells, CD4+ T cells, CD8+ T cells, B cells and NK cells was found negative for viral RNA.

Clinical outcome

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

We observed the clinical course of 25 COVID-19 patients within 23 days of treatment. During the first phase of treatment, at 8 - 14 days, fourteen

patients showed viral clearance and 12 of them were discharged from the hospital according to the guideline. The treatment of oxygen support therapy and clinical observation was continued for the remaining 2 patients in this group. Eleven viral RNA positive patients received a second phase of treatment between 15–23 days. Until February 28, 7 of these 11 patients turned out to be viral RNA negative. Four of these 7 patients were then discharged from the hospital, while the other 3 (one had a liver disease and the other two still had significant clinical symptoms), together with the 4 patients who were still positive for viral RNA, were kept under treatment (Table 1). In total, 9 out of the 25 COVID-19 patients were still hospitalized after 23 days of clinical treatment.

DISCUSSION

271 In this report, we retrospectively investigated the changes of CD3+,

272 CD4+, CD8+, B, and NK cell counts in peripheral blood of 25 COVID-

19 patients during the viral infection and the mechanisms for viral

clearance. We found that restoration of CD3+, CD4+, CD8+ T cells, B

cells and NK cells was associated the viral clearance in COVID-19

276 patients.

277 According to the Guideline of the treatment of COVID-19 (Version 6, 278 2020 Feb 18, 279 http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351 280 d7da8aefc2.shtml), the diagnosis of COVID-19 infection is based on an 281 epidemiological history of contact with COVID-19 patients or travel to 282 endemic areas, combined with laboratory testing including viral RNA 283 detection and radiological findings. COVID-19 patients have similarities 284 of the clinical features with other coronavirus infections. Most patients 285 had fever, cough, myalgia and fatigue, and less often showed symptoms 286 of dyspnoea, haemoptysis and diarrhea [10]. Half of the cases had 287 comorbidities such as diabetic, hypertension and cardiovascular diseases 288 [10]. In our study, we also found some cases that had underlying diseases 289 but without any association with the disease outcome. Age is a risk factor 290 for a more severe disease outcome, because of the generally inferior 291 function of the immune system among older people. Based on the 292 guideline, the patients who have normal body temperature for more than 293 three days, mitigation of respiratory symptoms, improvement of 294 radiological evidences for lesions, and had been tested negative for 295 specific SARS-CoV-2 RT-PCR at least twice, can be discharged from the 296 hospital. The average hospitalized time was 17 days (IQR 11.5 - 21.5), 297 and even as long as 23 days for the patients that were released from our 298 study [5], suggesting the time for SARS-CoV-2 clearance is also around

299 17 days or longer. This was also been observed in an earlier study where 300 the shedding of SARS-CoV-2 in saliva continued up to 11 days [17]. 301 Until now, there is no effective antivirals available against SARS-CoV-2. 302 To eliminate the virus an effective immunological response with a 303 minimum of immunopathological effects is required [18]. The antigen 304 presentation requires inhibitory alveolar macrophages and dendritic cells 305 (DCs). Successful stimulation can produce viral specific CD4 T cells, 306 which are involved in the development of a specific humoral response, 307 including neutralizing antibodies that can block the viral entry to the cells 308 [19]. CD8+ cytotoxic T cells are required for recognition and killing of 309 the infected cells, further playing a crucial role in SARS-CoV clearance 310 [20, 21]. However, in the biopsy samples from the patients who died of 311 COVID-19, histological examination showed pulmonary oedema with 312 hyaline membrane formation, and interstitial mononuclear inflammatory infiltrates in the lung tissue, suggesting that acute respiratory failure was 313 314 the cause of death, underlying mechanism that an over-activated 315 immunity injured the lung tissue [12]. Among SARS patients, high 316 expression of dysregulated chemokines and cytokines were found in 317 blood and lungs [22], due to the reason of aberrant immune response 318 caused by the viruses [13, 14]. The delayed or suboptimal immune 319 responses would make chances for SARS-CoV and MERS-CoV to

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

escape from the immune responses, and survive and replicate in the host cells, leading a further delay of the viral clearance [15, 23]. In our study, COVID-19 patients at older ages needed a longer time for the recovery, likely due to the fact that aging is associated with a set of functional and structural alterations in the immune system [24]. Immune-modulators, as corticosteroids, have been empirically used in both SARS and COVID-19 patients [10, 25]. Since corticosteroids might have a decline effect of circulating specific B and T cell subsets [26], the usage on COVID-19 patients should be carefully evaluated before considered [12, 27]. A rapid and generalized lymphopenia has been observed as a prominent part in SARS-CoV and MERS infections [28]. Lymphopenia has also been observed in other viral infections such as measles virus and avian influenza virus, swine foot-and-mouth disease virus, respiratory syncytial virus, and HIV [29-33]. The possible reasons would be lymphocyte sequestration in the lung tissues, or immune-mediate lymphocyte destruction. In MERS infections, the function of bone marrow or thymus suppressed, and furthermore, T cells underwent apoptosis [34-36]. In COVID-19 patients, peripheral CD4 and CD8 T cell counts were found decreased but, they were also hyperactivated, which could result in severe immune injuries [12].

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

In the present study, we followed the current guidelines and used a specific SARS-CoV-2 realtime RT-PCR for viral detection. Surprisingly, one lymphopenia patient (37y, male, chronic liver disease) was found negative by the realtime RT-PCR and his symptoms had been improved but he is still in hospital. Until now, specific viral RNA detection based on realtime RT-PCR is commonly used in the clinical diagnosis. The usage of realtime RT-PCR is versatile in the detection of SARS-CoV-2 in the respiratory tract specimen or throat swab, but we must keep in mind that those methods always are followed by the probability of false positive/negative. Besides, around 14% of the discharged COVID-19 patients were tested as positive again on follow up samples (https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19patients-in-guangdong-tested-positive-again-101520415.html), showing the recurrence of SARS-CoV-2. This imply that viral detection cannot be used as a single criterion for COVID-19 diagnosis. As a highly contiguous disease with a fatality of approximately 2.3% and up to 49.0% in critical cases [7], every hospitalized COVID-19 patient must be evaluated carefully before discharged. The peripheral leukomonocytes counts could provide more information in the evaluation of COVID-19 patients.

In conclusion, we retrospectively analyzed 25 COVID-19 cases and found that restoration of peripheral leukomonocytes could help the clearance of SARS-CoV-2. We propose here that leukomonocytes counts may serve as a valid prognosis of immune reconstitution for recovery of COVID-19 infection and that can update the current COVID-19 diagnosis guideline.

Acknowledgement

367

373

374

- 368 An especially strong appreciation goes to all the clinical physicians,
- 369 health caregivers, clinical laboratory personals, epidemiologists, and
- 370 researchers who have been fighting against the SARS-CoV-2 epidemic.
- 371 We also acknowledge the supports from both nationwide and
- international resources.

Reference

- 1. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med **2020**.
- Naming the coronavirus disease (COVID-2019) and the virus that causes it.
 Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
- 381 3. Available at: https://promedmail.org/.
- 382 4. Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol **2020**.
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized
 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
 JAMA 2020.
- Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med **2020**; 382(8): 727-33.
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a
 Report of 72314 Cases From the Chinese Center for Disease Control and
 Prevention. JAMA 2020.
- 394 8. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA **2020**.
- 396 9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature **2020**.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet **2020**; 395(10223): 497-506.
- 400 11. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet **2020**; 395(10223): 514-23.
- 403 12. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med **2020**.

- Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ **2003**; 326(7403): 1358-62.
- 408 14. Lau SK, Lau CC, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol **2013**; 94(Pt 12): 2679-90.
- 412 15. Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol **2020**.
- 415 16. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet **2020**.
- 418 17. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis **2020**.
- 420 18. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin 422 Immunopathol **2016**; 38(4): 471-82.
- 423 19. Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe 424 acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent 425 BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J 426 Virol **2010**; 84(3): 1289-301.
- Janice Oh HL, Ken-En Gan S, Bertoletti A, Tan YJ. Understanding the T cell immune response in SARS coronavirus infection. Emerg Microbes Infect **2012**; 1(9): e23.
- Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol **2010**; 84(18): 9318-25.
- Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med **2005**; 171(8): 850-7.
- 436 23. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep **2016**; 6: 25359.
- 439 24. Sadighi Akha AA. Aging and the immune system: An overview. J Immunol 440 Methods **2018**; 463: 21-6.
- 441 25. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med **2006**; 3(9): e343.
- Olnes MJ, Kotliarov Y, Biancotto A, et al. Effects of Systemically Administered Hydrocortisone on the Human Immunome. Sci Rep **2016**; 6: 23002.
- 445 27. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature **2020**.
- Li T, Qiu Z, Zhang L, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis **2004**; 189(4): 648-51.
- Okada H, Kobune F, Sato TA, et al. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Arch Virol **2000**; 145(5): 905-20.
- 453 30. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol **2002**; 76(9): 4420-9.

- 455 31. Bautista EM, Ferman GS, Golde WT. Induction of lymphopenia and inhibition of T cell function during acute infection of swine with foot and mouth disease virus (FMDV). Vet Immunol Immunopathol **2003**; 92(1-2): 61-73.
- 458 32. O'Donnell DR, Carrington D. Peripheral blood lymphopenia and neutrophilia in children with severe respiratory syncytial virus disease. Pediatr Pulmonol **2002**; 34(2): 128-30.
- 461 33. Li CX, Li YY, He LP, et al. The predictive role of CD4(+) cell count and
 462 CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients
 463 receiving antiretroviral therapy: an eight-year observation in China. BMC
 464 Immunol **2019**; 20(1): 31.
- He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis **2005**; 9(6): 323-30.
- 468 35. Yang Y, Xiong Z, Zhang S, et al. Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem J **2005**; 392(Pt 1): 135-43.
- 471 36. Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome 472 Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine 473 Development. J Immunol Res **2019**; 2019: 6491738.

Table 1. Demographics, baseline characteristics, treatment, and clinical outcomes of 25 patients infected with SARS-CoV-2

	Total	Viral clearance	without viral	P value
	(n=25)	(n=14) ^a	clearance	
			$(n=11)^a$	
Sex				
female	14(56.0%)	9(64.3%)	5(45.5%)	0.435
male	11(44.0%)	5(35.7%)	6(54.5%)	
Huanan Seafood Wholesale	14 (56.0%)	9 (64.3%)	5 (45.5%)	0.697
Market or patient infected with				
SARS-CoV-2 exposure				
Age, mean ±SD, y	51.4 ± 11.6	44.5 ± 13.0	60.2 ± 16.9	0.015
Comorbidities				
Hypertension	3(12.0%)	0(0.0%)	3(25.0%)	0.072
Cardiovascular disease	2(8.0%)	1(7.0%)	1(9.1%)	1.000
Diabetes	2(8.0%)	0(0.0%)	2(18.2%)	0.183
Malignancy	1(4.0%)	0(0.0%)	1(9.1%)	0.440
COPD	0(0.0%)	0(0.0%)	0(0.0%)	-
Chronic liver disease	3(12.0%)	0(0.0%)	3(25.0%)	0.072
Signs and symptoms				
Fever	18 (75.0%)	8 (57.1%)	10 (90.9%)	0.090
Fatigue	20 (80.0%)	11 (78.6%)	9 (81.8%)	1.000
Myalgia	17 (68.0%)	8 (57.1%)	9 (81.8%)	0.234
Cough	16 (64.0%)	9 (64.3%)	5 (45.5%)	0.697
Dyspnea	7 (28.0%)	4 (28.6%)	3 (27.3%)	1.000
Diarrhea	5 (20.0%)	2 (14.3%)	3 (27.3%)	0.623

Headache	2 (8.0%)	0 (0.0%)	2 (13.3%)	0.183
Heart rate, mean ±SD, bpm	88.2±15.1	86.8±11.8	89.9±18.9	0.617
Respiratory rate, median (IQR)	20.0 (19.0, 22.0)	20.0 (19.0, 22.0)	20.0 (19.0, 22.0)	0.845
Mean systolic blood pressure,	130.0 ± 24.4	126.8 ± 22.6	134.2 ± 27.1	0.464
mean ±SD, mm Hg				
Days from illness onset to	6 (3,11)	8 (3,11)	6 (3,11)	1.000
hospital, median (IQR), d				
Hospital stays, median (IQR), d	17.0 (11.5, 21.5)	12.0 (10.0,15.0)	21.0 (18.0,23.0)	0.001
Treatment				
Oxygen support	15 (60%)	6 (42.9%)	9 (81.8%)	0.099
Antiviral therapy	24(96.0%)	13(92.9%)	11(100.0%)	1.000
Antibiotic therapy	25(100.0%)	14(100.0%)	11(100.0%)	-
Use of corticosteroid	14 (56.0%)	6(42.9%)	8(72.7%)	0.227
Clinical outcome ^b				
Remained in hospital	9(36.0%)	2(14.3%)	7(63.6%)	0.017
Discharged	16(64.0%)	12(85.7%)	4(36.4%)	

^{479 &}lt;sup>a</sup> After 7-14 days, viral clearance or not was determined by viral RNA detections.

^b After 18-25 days, patients were discharged according to the guideline: 1) a series negative result of viral RNA detection; 2) no clinical symptoms; 3) improved chest CT imaging.

Table 2. Laboratory results of 25 patients with the outcome of viral clearance.

	Normal	Total	Viral clearance(n=14)	without viral	P value	
	Range			clearance (n=11)		
White blood cell Count (×10°/L)	3.5-9.5	4.5±1.9	4.5±1.7	4.5±2.2	0.919	
Lymphocyte count (×10° /L)	1.1-3.2	0.9 (0.6, 1.3)	0.8 (0.6, 1.4)	0.9 (0.6, 1.2)	0.565	
Monocyte count (×10° /L)	0.1-0.6	0.37±0.15	0.33±0.15	0.42±0.14	0.117	
Neutrophil count (×10 ⁹ /L)	1.8-6.3	2.8 (1.5, 4.5)	3.1 (1.6, 4.8)	2.6 (1.3, 4.3)	0.805	
Platelet count (×10° /L)	125-350	179.5±68.8	191.5±70.4	164.3±66.7	0.336	
Alanine aminotransferase (U/L)	9-50	24 (20.5, 38.5)	21 (19, 50.5)	25 (21.0, 35.0)	0.583	
Aspartate aminotransferase (U/L)	15-40	26 (21.0, 33.0)	23.0(17.0, 34.8)	28.0(26.0,33.0)	0.066	
Total bilirubin (mmol/L)	5-21	9.6 (8.0, 12.7)	9.6 (7.6, 12.2)	10.7 (8.2, 16.7)	0.511	
Lactate dehydrogenase (U/L)	125-243	197(164.5, 286.5)	197.0(155.0, 340.0)	201.0(174.0, 279.0)	0.956	
Prothrombin time (s)	9.4-12.5	12.3 (11.7, 13.0)	12.6 (11.7,13.5)	12.3 (12.1,12.4)	0.641	
Activated partial thromboplastin time (s)	25.1-36.5	29.9±3.0	29.8±2.6	30.0±3.6	0.860	
D-dimer, (mg/L)	0-500	187.0 (125.0,309.5)	181.0 (104.5,271.0)	233.0 (145.0,630.0)	0.179	
Creatinine (µmol/L)	64-104	65.5±14.6	64.3±14.3	67.0±15.6	0.659	
Procalcitonin, ng/mL ≥0.05, No. (%)	< 0.05	5 (20.0%)	3 (21.4%)	2 (18.2%)	1.000	
Interleukin-6 (pg/ml)	0-7	16.1 (3.7, 31.4)	13.8 (5.3, 30.2)	17.6 (2.8, 49.9)	0.805	
CD3+ T cell count (×10° /L)	805-4459	561.0 (338.0, 770.0)	639.0 (400.3, 1038.0)	485.0 (384.0, 732.0)	0.311	
CD4+ T cell count (×10° /L)	345-2350	297.0 (171.5, 447.5)	327.0 (182.8, 560.5)	220.0 (148.0, 420.0)	0.262	
CD8+ T cell count (×10° /L)	345-2350	272.9±129.7	291.4±149.3	249.5±101.6	0.435	
B cell count (×10° /L)	240-1317	111.5±75.8	133.2±84.8	83.8±54.2	0.107	
NK cell count (×10° /L)	210-1514	170.0 (67.5, 245.0)	193.5 (75.0, 286.0)	170.0 (43.0, 215.0)	0.511	

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

Figure legends **Figure 1.** Comparison of peripheral changes in CD3+, CD4+, CD8+ T, B, and NK cell counts in patients who were negative for the SARS-CoV-2 (A-E) and positive (F-J) after 8-14 days of treatment. The medium number of peripheral lymphocyte counts are represented in the solid line. The threshold of normal peripheral lymphocyte counts is represented in the dash line. NS means no significant difference tested in statistical analysis: Mann-Whitney U test was used for A, B, E, F since these data are non-normal distributed and t-test was used for the other normal distributed data). **Figure 2.** Comparison of peripheral changes in CD3+, CD4+, CD8+ T, B, and NK cell counts in six patients who were negative for the SARS-CoV-2 (A-E) and four patients who were positive (F-J) after 15-23 days of treatment. The medium number of peripheral lymphocyte counts are represented in the solid line. The threshold of normal peripheral lymphocyte counts is represented in the dash line. NS means no significant difference tested in statistical analysis and all data used Mann-Whitney U test.



